Celtaxsys company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.



Series E | Alive

Total Raised


About Celtaxsys

Celtaxsys is a clinical-stage pharmaceutical development company focused on advancing novel foundational therapies to treat inflammation in rare, orphan designated diseases. The company's flagship investigational medicine, oral once daily acebilustat, is aimed at preserving lung function in cystic fibrosis (CF) by specifically modulating key aspects of a dysregulated (i.e. over-activated) immune response.

Celtaxsys Headquarter Location

201 17th Street Suite 530

Atlanta, Georgia, 30363,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Celtaxsys

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Celtaxsys is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Celtaxsys Patents

Celtaxsys has filed 24 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Autoimmune diseases
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immunology, G protein coupled receptors, Immune system, Eicosanoids


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immunology, G protein coupled receptors, Immune system, Eicosanoids



Latest Celtaxsys News

Top Scenario: LIFESTYLE DRUGS Market 2018 | Focusing on Top Key Players like AndroScience, Anterios, AstraZeneca, Avanir Pharmaceuticals, Avolynt, Celtaxsys, Cerecor, Corcept Therapeutics, etc.

Nov 5, 2018

LIFESTYLE DRUGS Market Lifestyle drug is an term commonly applied to medications which treat non-life-threatening and non-painful conditions such as baldness, wrinkles, erectile dysfunction, or acne, which the speaker perceives as either not medical problems at all or as minor medical conditions relative to others. Proponents point out that improving the patient’s subjective quality of life has always been a primary concern of medicine. There is direct impact of lifestyle drugs on society, particularly in the developing world. Implications associated with labeling of indications and products sales of these lifestyle drugs may be varied. Drugs can, over time, switch from ‘lifestyle’ to ‘mainstream’ use. Lifestyle Drugs is also used in adults and children to treat Crohn’s disease or juvenile idiopathic arthritis. Global Lifestyle Drugs Market 2018-2023, has been prepared on the basis of an in-depth market analysis with from industry experts. The report also includes a debate of the leading players working in this market. In order to calculate the  Lifestyle Drugs market  size, the report considers the revenue generated from services provided to end-users such as the pharmaceutical and healthcare companies, medical device manufacturers, contract research organizations, biotechnology companies, and academic and research institutes. Request for Sample report at:  https://www.reportsweb.com/inquiry&RW00012270377/sample   The market research report on the Global Lifestyle Drugs Market by Reports Web is a prominent part of the pharmaceutical and healthcare portfolio and offers insights into the leading trends in the market and potential drivers, including the growth of the Global Lifestyle Drugs Market Industry. The report undergoes a detailed procedure of data collection methodology and presents an in-depth analysis of all the market segments and sub-segments. Any Query or Specific Discount Requirement? Ask our Industry Expert @  https://www.reportsweb.com/inquiry&RW00012270377/discount    Some of the major players operating in the Global Lifestyle Drugs Market include: Allergan, BMS, Eli Lilly, Pfizer, Acerus Pharmaceuticals, Alkermes, Amorepacific, AndroScience, Anterios, AstraZeneca, Avanir Pharmaceuticals, Avolynt, Celtaxsys, Cerecor, Corcept Therapeutics, Cosmo Pharmaceuticals, CTC Bio, Dermira, Dong-A ST, Euthymics Bioscience, Foamix, Follicum, Forendo Pharma, Futura Medical Developments, Galderma, Lifestyle Drugs Market: Product Segment Analysis: Depression, Dermatology, Sexual dysfunction, Obesity, Lifestyle Drugs Market: Application Segment Analysis Children, Adults, Senior Citizens, Competitive Landscape: Global Lifestyle Drugs Market The Global Lifestyle Drugs Market is highly fragmented and is based on new product launches, product advances, and clinical results of products. Therefore, the leading competitors have made use of different strategies, including new product launches, product advances, clinical trials, assumptions and methodologies, high investments on R&D, market initiatives, joint ventures, mergers & acquisitions, agreements, partnerships, and collaborations, to increase their presence in the market. What the report offers: Market Definition, including the product definition and the identification of key drivers and restraints for the market. Market analysis for the Global Lifestyle Drugs Market, with region-specific assessment and competitive landscape on a global and regional basis. Different factors that are instrumental in changing the market situations, emerging growth opportunities, and identification of key companies, which can affect the market on a global and regional scale. Thoroughly researched competitive scenario with the profiles of leading competitors along with their strategic initiatives and market shares. Identification and analysis of the macro and micro factors that affect the Global Lifestyle Drugs Market on both global and regional scale. A complete list of major market participants, including the analysis of their present strategies, investments, and key financial data. Access Full Report Description, TOC and Table of Figure @  https://www.reportsweb.com/inquiry&RW00012270377/buying The research report studies the market landscape and its growth prospects during the forecast period. Several research tools such as Porter’s five forces analysis, SWOT analysis, and so on. Have been exercised to provide a precise understanding of the overall market. The market research report provides an in-depth analysis of the major trends and technologies that are playing an important role in the growth of the market over the coming years. The study provides a detailed assessment of Global Lifestyle Drugs Market, in terms of revenue, throughout the aforementioned period. About ReportsWeb: ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Contact Us:

Celtaxsys Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Celtaxsys Rank

  • Where is Celtaxsys's headquarters?

    Celtaxsys's headquarters is located at 201 17th Street, Atlanta.

  • What is Celtaxsys's latest funding round?

    Celtaxsys's latest funding round is Series E.

  • How much did Celtaxsys raise?

    Celtaxsys raised a total of $52.7M.

  • Who are Celtaxsys's competitors?

    Competitors of Celtaxsys include PDS Biotechnology, Keryx Biopharmaceuticals, Larimar Therapeutics, Versartis, VLST Corporation and 11 more.

You May Also Like

Halsa Pharmaceuticals

Halsa Pharmaceuticals is a biotechnology company developing therapeutics for the treatment of obesity, diabetes, cachexia and other metabolic diseases.

Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.


REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.


LeukoSight Inc. is an early stage biotechnology company developing a line of therapeutics that can be used to treat autoimmune and inflammatory diseases.


XOMA (NASDAQ: XOMA) is a biotechnology company focused on the discovery and development of monoclonal antibody-based therapeutics. The Company is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. XOMA's product candidates are the result of developing monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases.

Kylin Therapeutics Logo
Kylin Therapeutics

Kylin Therapeutics, a biotechnology company, employs a RNA nanoparticle technology platform called"pRNA" to exploit the potential of RNA interference (RNAi) for treatment of many common diseases including cancer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.